Inovio Successfully Develops First DNA-Encoded Monoclonal Antibody (dMAb™) Checkpoint Inhibitor and Demonstrates Tumor Shrinkage in Preclinical Studies
October 08, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the successful animal testing of DNA-encoded monoclonal antibodies targeting the...
Major Cancer Journal Highlights Data From An Inovio-Sponsored Trial In Which A Patient Achieved Full Remission After Dosing With DNA Immunotherapy and Checkpoint Inhibitor
October 02, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today a paper published in a major cancer journal detailed results of a patient with head...
Inovio, 교차 반응을 일으키며 전임상 치사 시험에서 완벽한 예방 효과를 보인 H3N2 인플루엔자 DNA 백신 개발
September 17, 2018 22:12 ET
|
Inovio Pharmaceuticals, Inc.
H3N2 바이러스는 지난 50년간 가장 치명적인 독감 바이러스로 손꼽혀계절성 인플루엔자 백신의 효과가 가장 낮은 바이러스와도 일치전임상 연구는 NIH(미국 국립보건원)에서 지원 미국 펜실베이니아주 플리머스미팅, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc.(NASDAQ: INO)는...
Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges
September 17, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
H3N2 virus has been one of the most deadly flu strains in the past 50 years;And is always matched with the least effective seasonal influenza vaccine Preclinical work is supported by an NIH grant ...
Inovio, 메르스 백신 1/2 임상연구 피험자에 첫 접종
September 06, 2018 02:17 ET
|
Inovio Pharmaceuticals, Inc.
미국 펜실베이니아주 플리머스미팅, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc.(나스닥명: INO)가 메르스 바이러스(중동호흡기증후군) 감염을 예방하는 백신 INO-4700(GLS-5300)의 임상 1/2a상 연구에서 첫 번째 피험자에 대한 접종을 진행했다고 발표했다. 이번 임상시험은...
Inovio Doses 1st Subject in Phase 1/2 Clinical Trial For Vaccine Against Deadly MERS Infection
September 05, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today announced the dosing of the first subject with its vaccine to prevent infection...
Inovio와 한국 파트너사, 세계 최초의 C형 간염 감염 예방 백신 개발 임상시험에서 첫 피험자 투여
September 04, 2018 11:06 ET
|
Inovio Pharmaceuticals, Inc.
펜실베이니아주 플리머스 미팅 및 한국 서울, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc.(NASDAQ:INO)와 GeneOne Life Science(KSE: 011000)가 C형 간염 예방 백신의 효력을 평가하기 위한 제1상 임상시험에서 첫 환자에게 신약을 투여했다고 오늘 발표했다....
Inovio and Korean Partner Dose 1st Subject In Trial to Develop World’s First Vaccine to Prevent Hepatitis C Infection
September 04, 2018 01:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., and SEOUL, Korea, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and GeneOne Life Science (KSE: 011000) today announced they have dosed the first...
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
August 21, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that the Company will participate in the following upcoming investment...
Inovio Treats First Patient in Immuno-Oncology Study for Advanced or Metastatic Bladder Cancer in Combination with Roche/Genentech’s Atezolizumab
August 16, 2018 08:00 ET
|
Inovio Pharmaceuticals, Inc.
PLYMOUTH MEETING, Pa., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has dosed its first patient in a Phase 1/2a study designed to evaluate the...